Pembrolizumab with Chemotherapy in Urothelial and Prostate Cancers
Lay Title: Pembrolizumab with Chemo in Cancers of Urothelium and Prostate
Technical Title: Phase Ib Trial of Pembrolizumab (MK-3475) with Platinum-based Chemotherapy in Small Cell/Neuroendocrine Cancers of Urothelium and Prostate
Disease Type:Locally advanced or metastatic small cell/neuroendocrine cancers of the urothelium or prostate
Basic information: This study is being done to see how the experimental drug, pembrolizumab (also called MK-3475), will work in conjunction with standard of care chemotherapy consisting of etoposide and cisplatin/carboplatin or docetaxel and carboplatin to help people with small cell carcinoma of the urothelial or prostate.
Research Procedures (not a complete list):
If you participate in this study, you will receive your standard chemotherapy every treatment cycle, which is 3 weeks long, for 4 to 6 weeks. You will also receive pembrolizumab every treatment cycle, and will continue pembrolizumab for up to 35 weeks. Pembrolizumab is given to you through an IV infusion.
After you begin treatment, you will return to the clinic every 3 weeks. During these visits, you will have a physical exam, blood draws, and urine sample collection. Extra blood may be collected during the visits for research purposes.
You will continue to take pembrolizumab as long as our disease is not getting worse and you do not have bad side effects for up to 2 years.
Eligibility Criteria (not a complete list):
For More Detailed Information, contact:
Read more about this study (NCT03711032) on ClinicalTrials.gov.